Pharmacotherapeutic group: psychoanaleptics, other anti-dementia drugs; ATC code: N06DX02. The exact mechanism of action is not known.
Pharmacological data obtained in humans demonstrate increased EEG vigilance in geriatric subjects, decreased blood viscosity and improved cerebral perfusion in specific areas in healthy males (60 to 70 years), and decreased platelet aggregation. In addition, a vasodilatory effect in forearm vessels has been demonstrated, resulting in increased regional blood flow.
⚠️ Warnings
In patients with a pathologically increased tendency to haemorrhage and those concomitantly treated with anticoagulants and antiplatelet agents, this medicinal product should only be used with caution.
Products containing Ginkgo may increase susceptibility to bleeding; as a precautionary measure, this medicinal product must be discontinued 3 to 4 days before surgical procedures.
In patients with epilepsy, the onset of further seizures potentially potentiated by the use of Ginkgo-containing products cannot be excluded.
Concomitant use of Ginkgo biloba-containing products and efavirenz is not recommended (see section 4.5).
Gingio contains lactose monohydrate, spray-dried liquid glucose and sodium. This medicinal product contains lactose monohydrate and spray-dried liquid glucose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this product.
This medicinal product contains less than 1 mmol (23 mg) sodium per film-coated tablet, that is to say essentially "sodium-free".
